Good MorningEquity markets wobbled again on Wednesday as hotter than expected inflation data capped gains driven by better-than-expected earnings. Reports from the big banks reveal ongoing improvement in the consumer but that news was overshadowed by inflation fears. The producer price index, a leading indicator of consumer inflation, rose 1.0% from the previous month in an acceleration that drove year-over-year inflation to 7.3%.
The news was compounded by testimony from Fed Chief Jerome Powell who says that inflation has accelerated unexpectedly and that high inflation could linger for months. Even so, the FED Chief says there's no expectation for raising interest rates anytime soon. The next big test for the market will come over the next two days with the release of several important economic data points Featured: Sell these "safe" blue chips immediately (Ad) 
|
Finance | |
While DoorDash (NYSE: DASH) and Airbnb (NASDAQ: ABNB) are among the recent IPOs with the most buzz, they’re actually being trounced in the price-performance department by slightly older IPOs OneMain Holdings (NYSE: OMF), Customers Bancorp (NYSE: CUBI) and InMode (NASDAQ: INMD).
3 Underva... Read the Full Story |
|
From Our Partners | | Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief.
It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | | Watch the full story and see the verified track record for yourself |
|
Markets | |
A friend of mine spent over 10 years in a career that wasn't a great fit. She earned a meager salary, her bosses sighed every time it came time for performance reviews and she didn't advance in her role.
In turn, that affected her earnings, which affected her retirement savings, which affected h... Read the Full Story |
|
Finance | | Consumer borrowing is one of the key forces that drive the economy, which is why it's so great to see borrowing on credit cards and for auto and student loans surging as our financial system continues to recover from the impacts of the pandemic. The Federal Reserve recently reported that U.S. consum... Read the Full Story |
|
From Our Partners | | Moderna's stock doubled in a single day after its cancer vaccine hit key Phase 3 goals, and Merck jumped too. But according to a former Steve Cohen fund manager, the next big opportunity is not Moderna or Merck.
It is a different kind of company tied to a technology already backed by Elon Musk, Sam Altman, Jeff Bezos, and Peter Thiel. Nvidia's Jensen Huang says it will have a dramatic impact on daily life, while Anthropic's CEO believes it could unlock a century of medical progress in just ten years.
Nature Magazine estimates its potential value at $367 trillion globally, and it is already rolling out across the United States. | | Click here to learn about this new era of medical technology |
|
Finance | |
A Catch-22 For Wells Fargo
Wells Fargo (NYSE: WFC) is faced with a headwind that has emerged for the entire banking sector. The massive amounts of stimulus pumped into the economy are improving general conditions including consumer health and that is cutting into net interest income. The bank ma... Read the Full Story |
|
Healthcare | |
The Rebound Is On For Organigram
Organigram (NASDAQ: OGI), and the entire Canadian cannabis market, have been struggling in the wake of the COVID-19 pandemic. It's not that demand has evaporated so much as it is that stores have been closed and people can't get the product. But that's changing. C... Read the Full Story |
|
From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
|
Finance | |
In the universe of bank stocks, Bank of America (NYSE:BAC) is considered to be one of “the rest.” That is, that many investors view JPMorgan Chase (NYSE:JPM) and Goldman Sachs (NYSE:GS) as “the best.” Anything else pales in comparison.
I’m not going to debate that ... Read the Full Story |
|
Industrials | |
Fastenal Reports As-Expected Results
We don't want to imply that Fastenal (NASDAQ: FAST) is in bad shape because it's not. The problem that we are faced with is the same one that we were faced with when the company reported Q1 results. The results are 100% as expected, revenue is supported by pr... Read the Full Story |
|
Consumer Staples | | Consumer staple stocks like PepsiCo (NASDAQ:PEP) can be a great addition to any long-term portfolio, as they are known to hold up well in recessions and provide consistent dividend increases over the years. While they might not be as exciting as some of the cutting-edge tech stocks that have been dr... Read the Full Story |
|
Markets | |
I recently became part of the wave of people leaving their jobs during the "Great Resignation," the mass exodus of workers from their regular nine-to-five jobs. We must all think the grass is greener on the other side, huh? (You and I aren't the only ones. You can find 6 million more gig workers t... Read the Full Story |
|
Consumer Discretionary | |
Clothing retailers including Revolve Group (NYSE: RVLV), Boot Barn (NYSE: BOOT) and Lands’ End (NASDAQ: LE) are trading at new highs as customers spruce up long-neglected wardrobes.
As you might imagine, walk-in traffic is increasing at retail locations, but online ordering took off and bus... Read the Full Story |
|
The Early Bird Stock Of The Day Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany. | | View Today's Stock Pick |
|
